B. Riley Predicts Lower Earnings for Foghorn Therapeutics

Foghorn Therapeutics Inc. (NASDAQ:FHTX) – Research analysts at B. Riley lowered their Q2 2025 earnings per share estimates for shares of Foghorn Therapeutics in a research note issued to investors on Wednesday, May 14th. B. Riley analyst K. Patel now anticipates that the company will post earnings per share of ($0.36) for the quarter, down from their previous estimate of ($0.32). B. Riley has a “Strong-Buy” rating on the stock. The consensus estimate for Foghorn Therapeutics’ current full-year earnings is ($1.55) per share. B. Riley also issued estimates for Foghorn Therapeutics’ Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.47) EPS, FY2025 earnings at ($1.49) EPS, FY2026 earnings at ($1.44) EPS and FY2027 earnings at ($1.89) EPS.

Foghorn Therapeutics (NASDAQ:FHTX) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.30) earnings per share for the quarter, hitting the consensus estimate of ($0.30). The business had revenue of $5.95 million during the quarter, compared to analyst estimates of $4.96 million.

Several other equities research analysts have also recently issued reports on FHTX. Citigroup initiated coverage on Foghorn Therapeutics in a research note on Wednesday, April 23rd. They issued an “outperform” rating for the company. JMP Securities reiterated a “market outperform” rating and set a $9.00 target price on shares of Foghorn Therapeutics in a research report on Thursday, May 15th. HC Wainwright upgraded shares of Foghorn Therapeutics to a “strong-buy” rating in a research note on Wednesday, May 14th. Finally, Citizens Jmp began coverage on shares of Foghorn Therapeutics in a research report on Wednesday, April 23rd. They set a “mkt outperform” rating and a $9.00 price objective for the company. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $12.13.

Foghorn Therapeutics Stock Down 1.7%

Shares of NASDAQ:FHTX opened at $4.14 on Monday. Foghorn Therapeutics has a 12-month low of $2.94 and a 12-month high of $10.25. The company’s 50 day moving average price is $3.96 and its two-hundred day moving average price is $5.11. The firm has a market cap of $230.77 million, a PE ratio of -2.16 and a beta of 3.13.

Hedge Funds Weigh In On Foghorn Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. SCS Capital Management LLC bought a new stake in shares of Foghorn Therapeutics during the first quarter worth about $390,000. Jacobs Levy Equity Management Inc. grew its holdings in Foghorn Therapeutics by 8.1% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 241,816 shares of the company’s stock worth $883,000 after acquiring an additional 18,036 shares during the last quarter. AQR Capital Management LLC acquired a new position in Foghorn Therapeutics in the 1st quarter valued at approximately $68,000. DAFNA Capital Management LLC raised its stake in shares of Foghorn Therapeutics by 63.2% during the first quarter. DAFNA Capital Management LLC now owns 304,752 shares of the company’s stock valued at $1,112,000 after acquiring an additional 118,035 shares during the last quarter. Finally, Wellington Management Group LLP lifted its holdings in shares of Foghorn Therapeutics by 18.2% during the first quarter. Wellington Management Group LLP now owns 102,888 shares of the company’s stock worth $376,000 after purchasing an additional 15,819 shares during the period. Institutional investors and hedge funds own 61.55% of the company’s stock.

Foghorn Therapeutics Company Profile

Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.